Regeneron Pharmaceuticals Inc $350.46

up +3.54


29/8/2014 04:00 PM  |  NASDAQ : REGN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get REGN Trend Analysis - it has outperformed the S&P 500 by 22%

Partner Headlines

  1. Nasdaq, S&P 500 Rise In Lackluster Session; Tesla Gains

    IBD
  2. Nasdaq Leads Quiet, Pre-Holiday Session; NXP Breaks Out

    IBD
  3. Amgen edges up on trial results

    IBD
  4. Stocks Indexes Fall Modestly, Shaking Off Ukraine Unrest

    IBD
  5. Economic Data Fuel Another All-Time High For S&P 500

    IBD
  6. Qihoo, Regeneron Among 5 Stocks With Top Fundamentals

    IBD
  7. Jazz, Celgene Lead Top 4 Drugmaker Profit Margins

    IBD
  8. Drugmaker Q2 Profits Robust

    IBD
  9. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  10. Deutsche Bank Raises Regeneron's Price Target To $425

    Benzinga
  11. UPDATE: Regeneron Posts Upbeat Q2 Results

    Benzinga
  12. Earnings Scheduled For August 5, 2014

    Benzinga
  13. Len Schleifer's Science Focus Pays Off At Regeneron

    IBD
  14. Stocks End Mixed; Akamai Falls, Yelp Rises After Hours

    IBD
  15. Amgen Restructuring Plan, Q2 Earnings Send Stock Up

    IBD
  16. Stocks Thrash Out A Mixed Open; Buffalo Wild Wings Crumples

    IBD
  17. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD
  18. Stocks Recover Impressively; Gap Slumps In After Hours

    IBD
  19. Regeneron's Dupilumab Drug Headed For Phase Three Tests

    IBD
  20. Market Slides On European Bank Worries; Gold Stocks Rise

    IBD
  21. UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Following ...

    Benzinga
  22. Benzinga's Top #PreMarket Gainers

    Benzinga
  23. UPDATE: Regeneron, Sanofi Offer Positive Results from Phase 2b Study of ...

    Benzinga
  24. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  25. Pharmas Soar To New Highs

    IBD
  26. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  27. Stocks Rise In Strong Turnover; Netflix Soars On Upgrade

    IBD
  28. Regeneron Rises As Sanofi Raises Stake In Biotech

    IBD
  29. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  30. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  31. EYLEA Injection Recommended For Approval Regarding Treatment Of Visual ...

    Benzinga
  32. Auxilium Acquiring QLT For New Products, Low Taxes

    IBD
  33. Major Indexes Narrowly Lower As Actavis Rallies

    IBD
  34. Regeneron Shares Fall Following BMO's Note Of Roche Preference

    Benzinga
  35. US Stock Futures Edge Higher Ahead Of Jobless Claims, Retail Sales Data

    Benzinga
  36. US Stock Futures Tumble; World Bank Lowers Global Growth Outlook

    Benzinga
  37. Valeant EPS Tops, Sales Miss

    IBD
  38. Valeant Reports Mixed Q1 Amid Drug Earnings Bonanza

    IBD
  39. Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed

    IBD
  40. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  41. RBC Optimistic on Regeneron Following Lower Sales by Novartis' Lucentis

    Benzinga
  42. UPDATE: Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals ...

    Benzinga
  43. Benzinga's Top Initiations

    Benzinga
  44. Top 40 Upcoming Earnings Releases

    Benzinga
  45. Biotechs Struggling To Find A Bottom

    Benzinga
  46. Nasdaq Sheds 1% As China Growth Names, Biotechs Fall Hard

    IBD
  47. S&P 500 Edges Lower As Biotech Selling Weighs On Nasdaq

    IBD
  48. Cholesterol drug meets goal

    IBD
  49. Nasdaq Leads Another Up Day; S&P 500 Hits All-Time High

    IBD
  50. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
Trading Center